13 results on '"Murray, James L."'
Search Results
2. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
3. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells
4. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models
5. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin
6. Clinical pharmacology and tissue disposition studies of131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88
7. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer
8. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody
9. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy
10. Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organs
11. Decreased monocyte antibody-dependent cell-mediated toxicity in stage I–II malignant melanoma: Augmentation by subcutaneous Corynebacterium parvum
12. Ii-Key/HER-2/ neu MHC class-II antigenic epitope vaccine peptide for breast cancer
13. Clinical pharmacology and tissue disposition studies of131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88
- Abstract
Antibody LiCO 16.88 is a human IgM recognizing a 30- to 45-kDa intracytoplasmic antigen present in human adenocarcinoma cells. An 8-mg sample of antibody labeled with 5 mCi
131 I was co-administered i. v. with 120 mg (three patients), 240 mg (three patients) or 480 mg (four patients) unlabeled antibody as a 4-h infusion. The plasma half-life was 24±1.2 h and the immediate apparent volume of distribution was 5.2±0.2 l at the 28-mg dose level. The plasma half-lives and the cumulative urinary excretion of radiolabel did not seem to vary significantly with increasing doses of unlabeled antibody. However, both the volume of distribution and the clearance rate from plasma increased significantly with increasing antibody dose. Uptake of antibody into tumor tissues obtained during laparotomy 8–9 days after administration varied between 0.00002% ID/g and 0.00127% ID/g. In five of seven patients, the tumor content of antibody was higher than that in adjacent normal tissue. Tumor-to-normal tissue ratios ranged from 0.8 to 10 (!["]("/fulltext-image.asp?format=htmlnonpaginated&src=M240547151V6MT04_html\262_2005_Article_BF01534427_TeX2GIFIE1.gif")
=3.8±1.0). In general, the higher radioactivity(cpm)/g tumor was confirmed by both immunoperoxidase and autoradiography. Antibody 16.88 localizes in tumors after administration and may be considered for use in radioimmunotherapy trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.